{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:20:46Z","timestamp":1792120846540,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00277-024-06129-5","type":"journal-article","created":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T07:37:31Z","timestamp":1733557051000},"page":"5849-5859","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes"],"prefix":"10.1007","volume":"103","author":[{"given":"Darshi","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sparano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Krepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes M.","family":"Giesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Baldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eilidh","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Pe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajshekhar","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Efficace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,7]]},"reference":[{"key":"6129_CR1","first-page":"3","volume":"9","author":"SA Padala","year":"2021","unstructured":"Padala SA, Barsouk A, Barsouk A et al (2021) Epidemiology, Staging, and Management of Multiple Myeloma. Med Sci 9:3","journal-title":"Med Sci"},{"key":"6129_CR2","doi-asserted-by":"publisher","unstructured":"Abdallah NH, Smith AN, Geyer S et al (2023) Conditional survival in multiple myeloma and impact of prognostic factors over time. Blood Cancer J 13. https:\/\/doi.org\/10.1038\/s41408-023-00852-4","DOI":"10.1038\/s41408-023-00852-4"},{"key":"6129_CR3","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1038\/leu.2016.380","volume":"31","author":"R Fonseca","year":"2017","unstructured":"Fonseca R, Abouzaid S, Bonafede M et al (2017) Trends in overall survival and costs of multiple myeloma, 2000\u20132014. Leukemia 31:1915\u20131921","journal-title":"Leukemia"},{"key":"6129_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.33696\/haematology.4.055","volume":"4","author":"MJ Nieto","year":"2023","unstructured":"Nieto MJ, Hedjar A, Locke M et al (2023) Analysis of updates in multiple myeloma treatment and management. J Clin Haematol 4:35\u201342","journal-title":"J Clin Haematol"},{"key":"6129_CR5","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/ajh.25764","volume":"95","author":"R Chakraborty","year":"2020","unstructured":"Chakraborty R, Majhail NS (2020) Treatment and disease-related complications in multiple myeloma: Implications for survivorship. Am J Hematol 95:672\u2013690","journal-title":"Am J Hematol"},{"key":"6129_CR6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/bjh.18568","volume":"200","author":"T Etekal","year":"2023","unstructured":"Etekal T, Koehn K, Sborov DW et al (2023) Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. Br J Haematol 200:587\u2013594","journal-title":"Br J Haematol"},{"key":"6129_CR7","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1002\/ijc.31957","volume":"144","author":"TJ Hwang","year":"2019","unstructured":"Hwang TJ, Gyawali B (2019) Association between progression-free survival and patients\u2019 quality of life in cancer clinical trials. Int J Cancer 144:1746\u20131751","journal-title":"Int J Cancer"},{"key":"6129_CR8","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1182\/blood-2017-03-737403","volume":"130","author":"F Efficace","year":"2017","unstructured":"Efficace F, Gaidano G, Lo-Coco F (2017) Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice? Blood 130:859\u2013866","journal-title":"Blood"},{"key":"6129_CR9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/PROM.S156279","volume":"9","author":"R Mercieca-Bebber","year":"2018","unstructured":"Mercieca-Bebber R, King MT, Calvert MJ et al (2018) The importance of patient-reported outcomes in clinical trials and strategies for future optimization. Patient Relat Outcome Measures 9:353\u2013367","journal-title":"Patient Relat Outcome Measures"},{"key":"6129_CR10","doi-asserted-by":"publisher","first-page":"6007","DOI":"10.3390\/cancers14236007","volume":"14","author":"S Salek","year":"2022","unstructured":"Salek S, Ionova T, Oliva EN et al (2022) The Reporting, Use, and Validity of Patient-Reported Outcomes in Multiple Myeloma in Clinical Trials: A Systematic Literature Review. Cancers 14:6007","journal-title":"Cancers"},{"key":"6129_CR11","doi-asserted-by":"publisher","unstructured":"Fernandes LL, Zhou J, Kanapuru B et al (2021) Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement. Blood Cancer J 11. https:\/\/doi.org\/10.1038\/s41408-021-00543-y","DOI":"10.1038\/s41408-021-00543-y"},{"key":"6129_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B et al (1993) The european organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. JNCI J Natl Cancer Inst 85:365\u2013376","journal-title":"JNCI J Natl Cancer Inst"},{"key":"6129_CR13","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.clml.2022.01.009","volume":"22","author":"F Efficace","year":"2022","unstructured":"Efficace F, Cottone F, Sparano F et al (2022) Patient-reported outcomes in randomized controlled trials of patients with multiple myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021. Clin Lymphoma Myeloma Leuk 22:442\u2013459","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6129_CR14","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"6129_CR15","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1001\/jama.2013.879","volume":"309","author":"M Calvert","year":"2013","unstructured":"Calvert M, Blazeby J, Altman DG et al (2013) Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA 309:814\u2013822","journal-title":"JAMA"},{"key":"6129_CR16","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1007\/s11136-022-03119-w","volume":"31","author":"R Mercieca-Bebber","year":"2022","unstructured":"Mercieca-Bebber R, Aiyegbusi OL, King MT et al (2022) Knowledge translation concerns for the CONSORT-PRO extension reporting guidance: a review of reviews. Qual Life Res 31:2939\u20132957","journal-title":"Qual Life Res"},{"key":"6129_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/jama.2017.21903","volume":"319","author":"M Calvert","year":"2018","unstructured":"Calvert M, Kyte D, Mercieca-Bebber R et al (2018) Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: The SPIRIT-PRO extension. JAMA 319:483\u2013494","journal-title":"JAMA"},{"key":"6129_CR18","doi-asserted-by":"publisher","first-page":"6519","DOI":"10.1200\/JCO.2022.40.16_suppl.6519","volume":"40","author":"M Gupta","year":"2022","unstructured":"Gupta M, Akhtar OS, Bahl B et al (2022) Is health-related quality of life (HRQoL) reporting keeping pace with new drug approvals in hematology and oncology: A five-year analysis of 245 drug approvals. J Clin Oncol 40:6519\u20136519","journal-title":"J Clin Oncol"},{"key":"6129_CR19","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1001\/jamainternmed.2018.4710","volume":"178","author":"B Kovic","year":"2018","unstructured":"Kovic B, Jin X, Kennedy SA et al (2018) evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology. JAMA Intern Med 178:1586","journal-title":"JAMA Intern Med"},{"key":"6129_CR20","doi-asserted-by":"publisher","unstructured":"Servetto A, Di Maio M, Salomone F et al (2023) Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes. BMC Med 21. https:\/\/doi.org\/10.1186\/s12916-023-02953-0","DOI":"10.1186\/s12916-023-02953-0"},{"key":"6129_CR21","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1093\/jnci\/djad152","volume":"115","author":"A Shahnam","year":"2023","unstructured":"Shahnam A, Nindra U, Desai J et al (2023) Time to deterioration of patient-reported outcomes as a surrogate of overall survival: a meta-analysis. JNCI: J Natl Cancer Inst 115:1475\u20131482","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"6129_CR22","doi-asserted-by":"publisher","first-page":"e200643","DOI":"10.1001\/jamanetworkopen.2020.0643","volume":"3","author":"N Marschner","year":"2020","unstructured":"Marschner N, Zacharias S, Lordick F et al (2020) Association of disease progression with health-related quality of life among adults with breast, Lung, pancreatic, and colorectal cancer. JAMA Netw Open 3:e200643","journal-title":"JAMA Netw Open"},{"key":"6129_CR23","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","volume":"21","author":"C Coens","year":"2020","unstructured":"Coens C, Pe M, Dueck AC et al (2020) International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. Lancet Oncol 21:e83\u2013e96","journal-title":"Lancet Oncol"},{"key":"6129_CR24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jclinepi.2021.07.013","volume":"139","author":"T Olivier","year":"2021","unstructured":"Olivier T, Haslam A, Prasad V (2021) Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials. J Clin Epidemiol 139:80\u201386","journal-title":"J Clin Epidemiol"},{"key":"6129_CR25","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1182\/blood.V92.9.3131","volume":"92","author":"JP Fermand","year":"1998","unstructured":"Fermand JP, Ravaud P, Chevret S et al (1998) High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 92:3131\u20133136","journal-title":"Blood"},{"key":"6129_CR26","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.clgc.2019.05.010","volume":"17","author":"R Shah","year":"2019","unstructured":"Shah R, Botteman M, Solem CT et al (2019) A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of nivolumab versus everolimus in advanced renal cell carcinoma (aRCC). Clin Genitourin Cancer 17:356-365.e1","journal-title":"Clin Genitourin Cancer"},{"key":"6129_CR27","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.eururo.2018.11.033","volume":"75","author":"EM Basch","year":"2019","unstructured":"Basch EM, Scholz M, De Bono JS et al (2019) Cabozantinib versus mitoxantrone-prednisone in symptomatic metastatic castration-resistant prostate cancer: A randomized phase 3 trial with a primary pain endpoint. Eur Urol 75:929\u2013937","journal-title":"Eur Urol"},{"key":"6129_CR28","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC et al (2016) International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328\u2013e346","journal-title":"Lancet Oncol"},{"key":"6129_CR29","doi-asserted-by":"publisher","first-page":"e46017","DOI":"10.2196\/46017","volume":"25","author":"J Lehmann","year":"2023","unstructured":"Lehmann J, de Ligt KM, Tipelius S et al (2023) Adherence to patient-reported symptom monitoring and subsequent clinical interventions for patients with multiple myeloma in outpatient care: Longitudinal observational study. J Med Internet Res 25:e46017","journal-title":"J Med Internet Res"},{"issue":"6","key":"6129_CR30","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/S1470-2045(23)00157-2","volume":"24","author":"M Pe","year":"2023","unstructured":"Pe M, Alanya A, Falk RS, Amdal CD, Bjordal K, Chang J et al (2023) Setting international standards in analyzing patient-reported outcomes and quality of life endpoints in cancer clinical trials-innovative medicines initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures. Lancet Oncol 24(6):e270\u2013e283","journal-title":"Lancet Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06129-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06129-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06129-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:15:53Z","timestamp":1735866953000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06129-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6129"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06129-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"28 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FE: had a consultancy or advisory role for AbbVie, Incyte, Syros, Novartis and JAZZ Pharmaceuticals, outside the submitted work. RC: Consulting\/Advisory Board-Janssen, Sanofi Pasteur, and Adaptive Biotech. ED is employed by Myeloma Patients Europe which receives grant funding and consultancy fees from pharmaceutical companies and public sources. None of the other authors report any conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"During the preparation of this work the author(s) did not use any AI technology.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI and AI-assisted technologies in the writing process"}}]}}